



DEPARTMENT OF PSYCHIATRY

WEEK OF MARCH 16-20, 2015

March 16-20, 2015

WWW.HSC.USF.EDU/PSYCH NEWSLETTER

MEETINGS

Thursday, March 19 RESIDENT LECTURES

PGY 1—4 and Child and Adolescent Psychiatry
Residents: Please see weekly didactic notice emails from the Education Office for scheduled topics and presenters.

Friday, March 20 THIRD YEAR MEDICAL STUDENTS

7:30-9 AM	Mid Rotation Feedback Sessions
9-11 AM	Jeopardy—Dr. Glenn Catalano
11-12 PM	Quiz No. 1

IN THE KNOW!!!

Happy Birthday

to Lucy Hou and Dr. Ankita Patel—both have birthdays on March 19!!!

THE CARTER JENKINS CENTER

presents on March 19th, at 7-10 PM: **Manejo de los Desordenes de la Atención.: Síntomas Principales, Pacientes co-mórbidos, Conocimientos Nuevos y Avisos** por el Dr. Humberto Nágera, Profesor Eméritos de Psiquiatría de la Universidad de Michigan y la Universidad del Sur de la Florida, Director El Carter-Jenkins Centro, Psicoanalista de Niños, Adolescentes y Adultos.

In this Issue:

Meetings	1
In the Know	1-3
Research Happenings	4-6

Continued on page 2

WEEK OF MARCH 16-20, 2015**NEWSLETTER, PAGE 2**

March 16-20, 2015

Welcome Dr. Glenn Currier!!!

Following a nationwide search, Glenn Currier, MD, MPH, has been appointed the new chair of the Department of Psychiatry and Behavioral Neurosciences.

Dr. Currier is coming to USF Health from the University of Rochester, School of Medicine, Department of Psychiatry, where he is professor of Psychiatry and Emergency Medicine and associate chair for Clinical Services. He starts here part time in April and will assume leadership of the department full time July 1st.



Glenn Currier, MD, MPH

Dr. Currier received his bachelor's degree in economics and political science at Colby College in his home state of Maine, and was a research associate at the Wharton Econometric Forecasting Associates prior to entering medical school. He holds an MD degree from the University of Pittsburgh and a master's degree in public health from Yale University, where he specialized in health services research. Following residency training in psychiatry and internal medicine at Yale, he completed a fellowship in emergency psychiatry at NYU-Bellevue Hospital in New York City. Before moving to Rochester several years ago, Dr. Currier was the director of Consultation Liaison and Emergency Psychiatry at Los Angeles County-University of Southern California Medical Center.

Dr. Currier is a member of the Psychiatry Clinical Practice Subcommittee of the American College of Emergency Physicians and a past president of the American Association for Emergency Psychiatry. He received the American Foundation for Suicide Prevention's Lifesaver's Research Award in 2009.

He is the author or co-author of more than 50 publications focused primarily on psychiatric research and treatment in emergency departments, particularly relevant to care of suicidal individuals and veterans.

Dr. Currier is the father of four teenagers—Tom, 19; Nick, 17; Amy, 15; and Mike, 13. He is an avid Great Lakes sailor, who says he looks forward to the challenge of saltwater sailing in a warmer climate.

We greatly appreciate Dr. Kailie Shaw's service as interim chair and look forward to having Dr. Currier onboard.

Continued on page 3

DEPARTMENT OF PSYCHIATRY

WEEK OF MARCH 16-20, 2015

NEWSLETTER, PAGE 3

March 16-20, 2015

IN THE KNOW!!!

2015 FACULTY & STAFF CAMPAIGN

The Morsani College of Medicine's faculty and staff make up about one sixth of ALL of the faculty and staff at USF, making it impossible for the University to reach its goal without our help. We are currently at 33 percent participation, and our goal is to reach 100 percent by the end of June 2015. It's important to remember that every dollar does make a difference. Please consider giving back to our department, and see firsthand the impact this campaign has on our day-to-day experiences at USF Health.

Below are our priority funds identified by the leadership:

250061 – Child Development Center Operating Fund

430010 – Psychiatry Operating Fund

256048 – Center for Infant & Child Development

256072 – Daniel Sprehe Memorial, USF Forensic Psychiatry

256260 – Robert Roskamp Chair in Biological Psychiatry

You can make a gift to any fund within the USF System and your gift will count towards our department's participation goal. To make your gift today, please click the link below, or for a paper contribution form, contact Paul DeCosta.

www.USF.edu/FSCC

DEPARTMENT OF PSYCHIATRY

WEEK OF MARCH 16-20, 2015

NEWSLETTER, PAGE 4

March 16-20, 2015

RESEARCH HAPPENINGS!

Now Enrolling – Mild Alzheimer's disease

This is a double-blind, placebo-controlled study to test the safety and effectiveness of an anti-amyloid antibody administered subcutaneously as a disease-modifying treatment in patients age 50 - 90 with mild AD. Stable dose of approved medications for AD will be permitted at study entry. Patients will undergo brain MRI exams for monitoring safety and response to study treatment. They will also undergo safety and cognitive testing. Patients must have a person with whom they are regular contact, who can accompany them to study visits. Please call Kathy at (813)974-7006 to make a referral.

Principal Investigator: Jean Fils, MD

T-FORCE study: Investigational Medication for Children and Adolescents with Tourette's Disorder

The primary purpose of this research study is to determine the safety and tolerability of an investigational medication (NBI-98854) for Tourette syndrome. Each child will be evaluated to determine his or her eligibility to participate in the research study. Each participant who qualifies will receive the investigational medication, study-related medical exams, and laboratory tests at no cost. As some of the medical appointments can be lengthy, many forms of entertainment will be available to participants at his or her study visits. Compensation for time and travel is also available. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Investigational Medication (Ecopipam) for Children and Adolescents with Tourette's Disorder

The purpose of this research study is to evaluate an experimental drug called ecopipam in children ages 7 to 17 with Tourette's syndrome. The drug has not been approved by the FDA. There will be eight study visits and six telephone call visits, totally about 4 months. For the first two weeks of the Study Drug Part 1, subject will slowly increase the number of tablets (50/50 placebo or ecopipam) and stay on a stable dose for 2 weeks before discontinuing the study drug. After at least 10 days, subject will be re-examined. Study Drug Part 3 will be very much like Study Drug Part 1: for the first two weeks of the Study Drug Part 3, the subject will slowly increase the number of tablets (50/50 placebo or ecopipam, opposite of part 1) and stay on a stable dose for 2 weeks before discontinuing the study drug. Compensation for time and travel is also available. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

DEPARTMENT OF PSYCHIATRY

WEEK OF MARCH 16-20, 2015

NEWSLETTER, PAGE 5

March 16-20, 2015

RESEARCH HAPPENINGS!

Investigational Medication (SD-809 [Deutetrabenazine]) for Adolescents with Tourette's Disorder

The purpose of this research study is to evaluate an investigational medication (SD-809 [Deutetrabenazine]) that may help reduce tics. Tetrabenazine is a drug that has been approved in several European Union countries and Canada for the treatment of various movement disorders including tics, and it has also been approved by the US Food and Drug Administration (FDA) for the treatment of involuntary movements associated with Huntington Disease. SD-809 is an investigational drug, meaning it has not been approved by the FDA. SD-809 has the same action as tetrabenazine; however, SD-809 is broken down in the body more slowly than tetrabenazine. These differences in break down and release may mean that SD-809: 1) may be taken fewer times a day and 2) may react differently in the body compared to tetrabenazine. Study participants must be 12-18 years old and diagnosed with Tourette's Disorder. The clinical trial will involve taking the experimental drug for an 8-week period. Study participants will be compensated for their time. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Investigational Medication (Bitopertin) for Adults with OCD

The purpose of this research study is to evaluate an investigational medication (bitopertin) for adults with OCD, and determine if patients treated with bitopertin and a selective serotonin reuptake inhibitor (SSRI) may experience fewer symptoms compared with those treated with SSRI only, a currently recommended treatment for OCD. To prequalify for this study, patients must be between the ages of 18 and 65 years, currently taking medication for OCD, and continue to have symptoms of OCD while on medication. Additional eligibility requirements will be discussed with all potential participants prior to enrollment. Reimbursement for travel may also be provided. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Cognitive-Behavioral Therapy (CBT) for Anxiety Disorders in Children with Autism Spectrum Disorder Research Study

The purpose of this research study is to examine the efficacy of a manualized cognitive behavioral therapy to treat anxiety disorders in children with autism spectrum disorders. Therapy sessions last approximately one hour a week for sixteen weeks. In addition, participants will be involved in a number of anxiety and developmental assessments free of charge. Children ages 6-17 years old are eligible to participate. Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch, PhD

Continued on page 6

DEPARTMENT OF PSYCHIATRY

WEEK OF MARCH 16-20, 2015

NEWSLETTER, PAGE 6

March 16-20, 2015

RESEARCH HAPPENINGS!

Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder

The purpose of this research study is to assess the efficacy of a form of Cognitive Behavioral Therapy (CBT), called Stepped Care CBT, that requires fewer therapy visits and utilizes family members as active components in treatment. Children and families who are interested must complete an initial assessment to determine eligibility.

Eligible participants must be between 8 and 17 years of age and have a primary diagnosis of Obsessive Compulsive Disorder. Once eligibility is determined, participants will be randomly assigned to receive Stepped Care CBT or standard CBT. Those receiving Stepped Care CBT begin treatment in "Step One" which includes 3 sessions with a therapist over the course of 6 weeks while being coached through a take-home workbook. If after 6 weeks it is determined by the research team that insufficient progress has been made, participants progress to "Step Two" which includes 9 additional therapy sessions over 9 weeks. Those receiving standard CBT will receive weekly therapy sessions for 12 weeks. Please contact Brittney Dane at (727) 767-7427 for more information.

Principal Investigator: Adam B. Lewin, PhD, ABPP

Parent-led Behavioral Treatment for Young Children with Problematic Anxiety

The purpose of this research study is to examine the effectiveness of a parent-led behavioral treatment for children ages 3 to 7 years old with problematic anxiety. Children and families who are interested must complete an initial assessment to determine eligibility. Once eligibility is determined, participants will be randomly assigned to receive 5 weeks of the parent-led behavioral treatment or a 5 week wait-list condition (followed by 5 weeks of the therapy intervention). Please call (727) 767-8230 for more information.

Principal Investigator: Adam B. Lewin, PhD, ABPP

For
information
regarding the
USF Memory
Disorders
Clinic, please
go to the
following
website:
www.health.usf.edu/medicine/psychiatry/memory_disorders.htm

DEPARTMENT OF PSYCHIATRY & BEHAVIORAL NEUROSCIENCES

Morsani College of Medicine
University of South Florida
3515 East Fletcher Avenue, MDT 1400
Tampa, FL 33613

www.hsc.usf.edu/PSYCH